Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)

Summary

This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.

Timeline

Start

2011-11-29

Primary completion

2012-11-06

Completion

2012-11-06

Outcome

Met primary endpoint

paper Seroprotection rates in mpHBV SC were non-inferior to that in Heptavax®-II SC PMID 29553862 ↗

Publications

• Results Kishino H, Takahashi K, Sawata M, Tanaka Y. Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults. Hum Vaccin Immunother. 2018 Jul 3;14(7):1773-1778. doi: 10.1080/21645515.2018.1452578. Epub 2018 Apr 12.

Drugs

Indications